Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9340078 | 0.90 | PTGS1 (0.59) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL764989 | 0.85 | SLC6A2 (0.67) | SLC6A2SLC6A3PTGS1PTGS2LMNA | |
| SCHEMBL8123372 | 0.82 | PTGS1 (0.56) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL14540062 | 0.82 | PTGS1 (0.52) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL14528263 | 0.82 | PTGS1 (0.52) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL6075401 | 0.81 | SLC6A2 (0.52) | SLC6A2SLC6A3PTGS1PTGS2LMNA | |
| SCHEMBL8229348 | 0.79 | SLC6A2 (0.59) | SLC6A2SLC6A3PTGS1PTGS2LMNA | |
| SCHEMBL1426754 | 0.78 | TSHR (0.50) | LMNATSHR | |
| SCHEMBL5099590 | 0.77 | SLC6A4 (0.54) | SLC6A2SLC6A3NFKB1TSHRBLM | |
| SCHEMBL4158699 | 0.77 | SLC6A2 (0.61) | SLC6A2SLC6A3LMNASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067538-B2 | MCP-1 receptor antagonists and methods of use thereof | WARNER-LAMBERT COMPANY, LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | BRATTON LARRY D (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1539685-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014847-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | CCR2, CCR1, CCL2 | SLC6A2 1533/4885SLC6A3 1045/4885PTGS1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.